Message #11 From:
NewsBot Date: December 22, 2005 10:02:00 AM
CYGX News CytoGenix Announces Completion of synDNA(TM) Production Module Prototype
HOUSTON--(BUSINESS WIRE)--Dec. 22, 2005--CytoGenix, Inc. (OTCBB:CYGX) announced that the prototype version of the synDNA(TM) production module was completed on schedule.
The device was designed specifically for the commercial production of cell-free DNA by the leading international biopharmaceutical plant design, engineering and construction firm of Alfa Laval Biokinetics, Philadelphia, Pennsylvania. It was tested by Alfa Laval engineers and CytoGenix senior scientists. The final version will be mounted on a stainless steel cart and have the capacity to produce up to 10 grams of high-purity DNA in 24 hours.
Kurt Berens, CytoGenix, Inc. Vice President of Product Development, commented, "This is an important step in our overall plan to construct a cGMP manufacturing facility. We plan to install several synDNA(TM) production modules to meet the growing demand for clinical-grade DNA internally and from customers."
About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission.
Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
